The professor of neurology at both the University of California San Francisco and King’s College, London, spoke about the results from a phase 2b/3 study evaluating atogepant for prevention of migraine.
"What it's suggesting is that if we understand enough about the mechanisms that are involved we can give patients a treatment that that they want for the problem they have rather than trying to shoehorn their problem into is it acute or is in prevention some big changes in the way we think about the treatment of migraine."
At the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pennsylvania, Peter Goadsby, MD, PhD, DSc, and colleagues presented the results from a phase 2b/3 study that evaluated the efficacy, safety, and tolerability of atogepant versus placebo for prevention of episodic migraine.
The data demonstrated that all 5 atogepant treatment arms showed statistically significant, clinically relevant differences from placebo in reductions from baseline in mean migraine days. Treatment-emergent adverse effects were reported by 480/834 subjects (58.2%); 170 (20.6%) were considered treatment related. Generally, atogepant was reported to be well tolerated and there were no treatment-related serious adverse effects.1
To further explain the results of the study, Goadsby sat down with NeurologyLive at the meeting for an interview.
1. Goadsby P, Dodick D, Trugman J, et al. Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study. Presented at: 2019 American Academy of Neurology Annual Meeting. May 4-10, 2019; Philadelphia, PA. Abstract S17.001.